Skip to main content

Advertisement

SpringerLink
Log in

Surveillance Biopsy After Lung Transplantation — Is It Necessary?

  • REVIEW
  • Published:
Current Pulmonology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Routine scheduled transbronchial surveillance biopsies allow for regular invasive assessment of allograft health and detection of alloimmune, infectious, inflammatory, or anastomotic conditions that may otherwise be clinically occult. An alternative approach to surveillance biopsies utilizes noninvasive assessments of allograft health and function combined with bronchoscopy when abnormalities are detected. There is an ongoing debate with reference to the merits and drawbacks of each approach.

Recent Findings

A large majority of lung transplant programs employ surveillance biopsies.  While the safety and ability of this approach to identify occult cellular rejection are established, the impact on longer term outcomes remains unclear.  An alternative approach utilizing biopsy triggered by clinical indications is limited by the inability to detect occult rejection and reliance on spirometry which may be an insensitive and non-specific biomarker of allograft health. Newer non-invasive monitoring approaches particularly those employing donor-derived cell free DNA may further reduce reliance on surveillance biopsy.

Summary

The impacts of monitoring with or without surveillance biopsy on long-term graft and patient health and survival have not been compared in a scientifically rigorous matter. Newer diagnostic tools may ultimately enhance non-invasive assessment of graft function and decrease reliance on surveillance biopsy.  This article will review available evidence and evolution in post-transplant care to evaluate the rationale, advantages, and drawbacks of these two practices.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ikeda S, Yanai N, Ishikawa S. Flexible bronchofiberscope. Keio J Med. 1968;17(1):1–16.

    Article  CAS  PubMed  Google Scholar 

  2. Smart J. Transbronchial pulmonary biopsy. Thorax. 1966;21(5):444.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hardy JD, Webb WR, Dalton ML, Walker GR. Lung homotransplantation in man. JAMA. 1963;186:1065–1074.

    Article  CAS  PubMed  Google Scholar 

  4. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med. 1982;306(10):557–564.

    Article  CAS  PubMed  Google Scholar 

  5. Group TLT. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med. 1986;314(18):1140–1145.

    Article  Google Scholar 

  6. Trulock EP, Ettinger NA, Brunt EM, Pasque MK, Kaiser LR, Cooper JD. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest. 1992;102(4):1049–1054.

    Article  CAS  PubMed  Google Scholar 

  7. Higenbottam T, Stewart S, Penketh A, Wallwork J. Transbronchial lung biopsy for the diagnosis of rejection in heart-lung transplant patients. Transplantation. 1988;46(4):532–539.

    Article  CAS  PubMed  Google Scholar 

  8. Martinu T, Koutsokera A, Benden C, et al. International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation. J Heart Lung Transplant. 2020;39(11):1171–1190.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Hopkins PM, Aboyoun CL, Chhajed PN, et al. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant. 2002;21(10):1062–7.

    Article  PubMed  Google Scholar 

  10. McWilliams TJ, Williams TJ, Whitford HM, Snell GI. Surveillance bronchoscopy in lung transplant recipients: risk versus benefit. J Heart Lung Transplant. 2008;27(11):1203–1209.

    Article  PubMed  Google Scholar 

  11. Chakinala MM, Ritter J, Gage BF, et al. Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation. J Heart Lung Transplant. 2004;23(12):1396–1404.

    Article  PubMed  Google Scholar 

  12. Takizawa DB, de Castro CCB, Paiva MA, et al. Surveillance bronchoscopy in lung transplantation recipients: a single center experience analysis. Transplant Proc. 2020;52(5):1380–1383.

    Article  PubMed  Google Scholar 

  13. Tosi D, Carrinola R, Morlacchi LC, et al. Surveillance transbronchial biopsy program to evaluate acute rejection after lung transplantation: a single institution experience. Transplant Proc. 2019;51(1):198–201.

    Article  CAS  PubMed  Google Scholar 

  14. Benden C, Harpur-Sinclair O, Ranasinghe AS, Hartley JC, Elliott MJ, Aurora P. Surveillance bronchoscopy in children during the first year after lung transplantation: is it worth it? Thorax. 2007;62(1):57–61.

    Article  CAS  PubMed  Google Scholar 

  15. Fruchter O, Fridel L, Rosengarten D, Raviv Y, Rosanov V, Kramer MR. Transbronchial cryo-biopsy in lung transplantation patients: first report. Respirology. 2013;18(4):669–673.

    Article  PubMed  Google Scholar 

  16. Gershman E, Ridman E, Fridel L, et al. Efficacy and safety of trans-bronchial cryo in comparison with forceps biopsy in lung allograft recipients: analysis of 402 procedures. Clin Transplant. 2018;32(4):e13221.

    Article  PubMed  Google Scholar 

  17. Loor K, Culebras M, Sansano I, Álvarez A, Berastegui C, de Gracia J. Optimization of transbronchial cryobiopsy in lung transplant recipients. Ann Thorac Surg. 2019;108(4):1052–1058.

    Article  PubMed  Google Scholar 

  18. Mohamed S, Mendogni P, Tosi D, et al. Transbronchial cryobiopsies in lung allograft recipients for surveillance purposes: initial results. Transplant Proc. 2020;52(5):1601–1604.

    Article  PubMed  Google Scholar 

  19. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007;26(12):1229–1242.

    Article  PubMed  Google Scholar 

  20. Valentine VG, Taylor DE, Dhillon GS, et al. Success of lung transplantation without surveillance bronchoscopy. J Heart Lung Transplant. 2002;21(3):319–326.

    Article  PubMed  Google Scholar 

  21. Valentine VG, Gupta MR, Weill D, et al. Single-institution study evaluating the utility of surveillance bronchoscopy after lung transplantation. J Heart Lung Transplant. 2009;28(1):14–20.

    Article  PubMed  Google Scholar 

  22. SRTR Program-Specific Report WAUW Lung. Scientific Registry of Transplant Recipients 2023.

  23. Meyer KC, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014;44(6):1479–1503.

    Article  PubMed  Google Scholar 

  24. Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-a consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019;38(5):493–503.

    Article  PubMed  Google Scholar 

  25. Hopkins PM, Aboyoun CL, Chhajed PN, et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med. 2004;170(9):1022–1026.

    Article  PubMed  Google Scholar 

  26. Hachem RR, Khalifah AP, Chakinala MM, et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation. 2005;80(10):1406–1413.

    Article  PubMed  Google Scholar 

  27. Levy L, Huszti E, Tikkanen J, et al. The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation. Am J Transplant. 2020;20(1):241–249.

    Article  PubMed  Google Scholar 

  28. Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med. 2008;177(9):1033–1040.

    Article  PubMed  Google Scholar 

  29. Burton CM, Iversen M, Scheike T, Carlsen J, Andersen CB. Is lymphocytic bronchiolitis a marker of acute rejection? An analysis of 2,697 transbronchial biopsies after lung transplantation. J Heart Lung Transplant. 2008;27(10):1128–1134.

    Article  PubMed  Google Scholar 

  30. Davis WA, Finlen Copeland CA, Todd JL, Snyder LD, Martissa JA, Palmer SM. Spirometrically significant acute rejection increases the risk for BOS and death after lung transplantation. Am J Transplant. 2012;12(3):745–752.

    Article  CAS  PubMed  Google Scholar 

  31. DeVito DA, Hoffman LA, Iacono AT, et al. Pattern and predictors of early rejection after lung transplantation. Am J Crit Care. 2003;12(6):497–507.

    Article  Google Scholar 

  32. Cho E, Wu JKY, Birriel DC, et al. Airway oscillometry detects spirometric-silent episodes of acute cellular rejection. Am J Respir Crit Care Med. 2020;201(12):1536–1544.

    Article  PubMed  Google Scholar 

  33. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study Group. J Heart Lung Transplant. 1996;15(1 Pt 1):1–15.

    CAS  PubMed  Google Scholar 

  34. Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2016;35(4):397–406.

    Article  PubMed  Google Scholar 

  35. Bhorade SM, Husain AN, Liao C, et al. Interobserver variability in grading transbronchial lung biopsy specimens after lung transplantation. Chest. 2013;143(6):1717–1724.

    Article  CAS  PubMed  Google Scholar 

  36. Arcasoy SM, Berry G, Marboe CC, et al. Pathologic interpretation of transbronchial biopsy for acute rejection of lung allograft is highly variable. Am J Transplant. 2011;11(2):320–328.

    Article  CAS  PubMed  Google Scholar 

  37. Chakinala MM, Ritter J, Gage BF, et al. Reliability for grading acute rejection and airway inflammation after lung transplantation. J Heart Lung Transplant. 2005;24(6):652–657.

    Article  PubMed  Google Scholar 

  38. Fisher AJ, Gabbay E, Small T, Doig S, Dark JH, Corris PA. Cross sectional study of exhaled nitric oxide levels following lung transplantation. Thorax. 1998;53(6):454–458.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Neurohr C, Huppmann P, Leuschner S, et al. Usefulness of exhaled nitric oxide to guide risk stratification for bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant. 2011;11(1):129–137.

    Article  CAS  PubMed  Google Scholar 

  40. The lung allograft regection gene expression observational study. https://clinicaltrials.gov/study/NCT00751309.

  41. Weigt SS, Wang X, Palchevskiy V, et al. Usefulness of gene expression profiling of bronchoalveolar lavage cells in acute lung allograft rejection. J Heart Lung Transplant. 2019;38(8):845–855.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Jang MK, Tunc I, Berry GJ, et al. Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study. J Heart Lung Transplant. 2021;40(8):822–830.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Khush KK, De Vlaminck I, Luikart H, Ross DJ, Nicolls MR. Donor-derived, cell-free DNA levels by next-generation targeted sequencing are elevated in allograft rejection after lung transplantation. ERJ Open Res. 2021;7(1).

  44. Sayah D, Weigt SS, Ramsey A, Ardehali A, Golden J, Ross DJ. Plasma donor-derived cell-free DNA levels are increased during acute cellular rejection after lung transplant: pilot data. Transplant Direct. 2020;6(10):e608.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Keller M, Sun J, Mutebi C, et al. Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care. J Heart Lung Transplant. 2022;41(4):458–466.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Puget Sound Veterans Administration, Puget Sound VA Medical Center, University of Washington, Box S111 Pulm, 1660 South Columbian Way, Seattle, WA, 98108, USA

    Jeffrey D. Edelman

Authors
  1. Jeffrey D. Edelman
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JE wrote and prepared the entire manuscript.

Corresponding author

Correspondence to Jeffrey D. Edelman.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Edelman, J.D. Surveillance Biopsy After Lung Transplantation — Is It Necessary?. Curr Pulmonol Rep (2024). https://doi.org/10.1007/s13665-024-00345-0

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13665-024-00345-0

Keywords

Search

Navigation